Fig. 1: miR-21 is associated with metastatic capacity of breast cancer and predicts poor clinical outcome.
From: MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms
a Volcano plot of differentially expressed miRNAs between non-metastatic 67NR and highly metastatic 4T1.2 mouse mammary tumour cells. b, c Expression of mature miR-21 levels in mouse mammary tumour cells (b) and in whole tumours (c) derived from the 4T1 model, with varying levels of metastatic capacity. MiR-21 expression was normalised to expression of Rnu6 small nuclear RNA (U6) and set to 1 in the non-metastatic 67NR line. Error bars in (b) represent mean ± SEM (n = 3). The mean and range (n = 2) is shown in (c). d The miR-21 gene at 17q23 is amplified in a subset of primary human breast cancers and is associated with higher tumour grade compared to non-amplified tumours (p = 2.11 ×10−8). e, f Higher levels of miR-21 expression in primary breast tumours are associated with poorer overall survival in the Metabric (n = 1262) and the TCGA (n = 1078) breast cancer patient datasets.
